Li-Jing Deng1, Feng Wang, Huan-De Li. 1. Clinical Pharmaceutical Research Institute, The Second Xiangya Hospital, The Central South University, Changsha 410011, China. denglijing7117@163.com
Abstract
OBJECTIVE: Our objective was to study the effects of gemfibrozil on the pharmacokinetics of pioglitazone and the active compounds, which are all the substrates of CYP2C8 and CYP3A4. METHODS: In a randomized, two-phase crossover study, 10 healthy volunteers were pretreated for 2 days with either 600 mg oral gemfibrozil or placebo twice daily. On day 3, they received a single dose of 600 mg gemfibrozil or placebo, and 1 h later they received a single oral dose of 30 mg pioglitazone. Plasma concentrations of pioglitazone and both active metabolites M-III and M-IV were measured for up to 120 h. RESULTS:Gemfibrozil raised the mean total area under the concentration-time curve (AUC) of parent pioglitazone 3.4-fold (P<0.001). No statistically significant changes were seen in the total AUC of M-III or M-IV after gemfibrozil pretreatment. Gemfibrozil reduced the M-III/pioglitazone and M-IV/pioglitazone AUC(0-infinity) ratio by 71% (P<0.001) and 65%(P<0.001), strikingly prolonging their t((1/2)). CONCLUSION:Gemfibrozil greatly increased the plasma concentration of parent pioglitazone and also inhibited the further metabolism of M-III and M-IV. Careful blood glucose monitoring and dosage adjustments are suggested during coadministration of pioglitazone and gemfibrozil.
RCT Entities:
OBJECTIVE: Our objective was to study the effects of gemfibrozil on the pharmacokinetics of pioglitazone and the active compounds, which are all the substrates of CYP2C8 and CYP3A4. METHODS: In a randomized, two-phase crossover study, 10 healthy volunteers were pretreated for 2 days with either 600 mg oral gemfibrozil or placebo twice daily. On day 3, they received a single dose of 600 mg gemfibrozil or placebo, and 1 h later they received a single oral dose of 30 mg pioglitazone. Plasma concentrations of pioglitazone and both active metabolites M-III and M-IV were measured for up to 120 h. RESULTS:Gemfibrozil raised the mean total area under the concentration-time curve (AUC) of parent pioglitazone 3.4-fold (P<0.001). No statistically significant changes were seen in the total AUC of M-III or M-IV after gemfibrozil pretreatment. Gemfibrozil reduced the M-III/pioglitazone and M-IV/pioglitazone AUC(0-infinity) ratio by 71% (P<0.001) and 65%(P<0.001), strikingly prolonging their t((1/2)). CONCLUSION:Gemfibrozil greatly increased the plasma concentration of parent pioglitazone and also inhibited the further metabolism of M-III and M-IV. Careful blood glucose monitoring and dosage adjustments are suggested during coadministration of pioglitazone and gemfibrozil.
Authors: Jasminder Sahi; Christopher B Black; Geraldine A Hamilton; Xianxian Zheng; Summer Jolley; Kelly A Rose; Darryl Gilbert; Edward L LeCluyse; Michael W Sinz Journal: Drug Metab Dispos Date: 2003-04 Impact factor: 3.922
Authors: Joseph E Rower; Lane R Bushman; Kyle P Hammond; Rajendra S Kadam; Christina L Aquilante Journal: Biomed Chromatogr Date: 2010-12 Impact factor: 1.902
Authors: Christina L Aquilante; Lisa A Kosmiski; David W A Bourne; Lane R Bushman; Elizabeth B Daily; Kyle P Hammond; Charles W Hopley; Rajendra S Kadam; Alexander T Kanack; Uday B Kompella; Merry Le; Julie A Predhomme; Joseph E Rower; Maha S Sidhom Journal: Br J Clin Pharmacol Date: 2013-01 Impact factor: 4.335
Authors: Christina L Aquilante; Michael F Wempe; Samantha H Spencer; Lisa A Kosmiski; Julie A Predhomme; Maha S Sidhom Journal: Pharmacotherapy Date: 2013-05-26 Impact factor: 4.705